84859-27-8

Basic information

• Product Name: 5-Chloro-N1-Methylbenzene-1,2-diaMine
• Synonyms: 5-Chloro-N1-Methylbenzene-1,2-diaMine;4-Chloro-N*2*-methyl-benzene-1,2-diamine
• CAS NO: 84859-27-8
• Molecular Formula: C₇H₉ClN₂
• Molecular Weight: 156.61276
• Mol File: 84859-27-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5-Chloro-N1-Methylbenzene-1,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-N1-Methylbenzene-1,2-diaMine(84859-27-8)
• EPA Substance Registry System: 5-Chloro-N1-Methylbenzene-1,2-diaMine(84859-27-8)

Safety Data

• Hazardous Substances Data: 84859-27-8(Hazardous Substances Data)

Usage

General Description

5-Chloro-N1-Methylbenzene-1,2-diamine is a chemical compound classified under organic compounds known as aniline and substituted anilines. These are compounds containing an aniline moiety, which consists of an o-, m-, or p-arene linked to an amino group. It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. However, its physical properties, biological activities, safety, and toxicity information are not well-documented, considering it does not appear to have many common applications. Like many chemicals, proper handling and care should be utilized to avoid potential hazards.

Upstream product

• 7647-01-0 hydrogenchloride 
• 35966-84-8 4-chloro-2-methylaminonitrobenzene 
• 1635-61-6 5-chloro-2-nitroaniline 
• 611-06-3 2,4-dichloronitrobenzene 
• 610-40-2 3,4-dinitro-chlorobenzene 

Downstream Products

• 108897-91-2 acetic acid-[2-(6-chloro-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-anilide] 
• 10406-94-7 1-methyl-6-chloro-1H-benzo[d]imidazole 
• 331949-55-4 (6-chloro-1-methyl-1H-benzimidazol-2-yl)-methanol 
• 77314-30-8 6-Chloro-1-methyl-2-p-tolyl-1H-benzoimidazole 
• 14537-47-4 6-Chlor-1,2-dimethyl-benzimidazol 
• 1191924-12-5 C₂₁H₁₆Cl₃N₅ 
• 19808-76-5 6-chloro-1-methyl-1H-benzimidazole-2-carbonitrile 
• 4926-65-2 5-chloro-2-phenyl-1H-benzimidazole 
• 50771-97-6 6-chloro-1-methyl-1H-benzimidazole-2-thiol 
• 15965-72-7 6-chloro-1,3-dihydro-1-methyl-2H-benzimidazol-2-one 
• 77314-35-3 4-Chloro-2-(6-chloro-1-methyl-1H-benzoimidazol-2-yl)-phenol 
• 77314-34-2 6-Chloro-2-(3,4-dichloro-phenyl)-1-methyl-1H-benzoimidazole 

Relevant articles and documents

Discovery of selective fragment-sized immunoproteasome inhibitors

Proteasomes contribute to maintaining protein homeostasis and their inhibition is beneficial in certain types of cancer and in autoimmune diseases. However, the inhibition of the proteasomes in healthy cells leads to unwanted side-effects and significant effort has been made to identify inhibitors specific for the immunoproteasome, especially to treat diseases which manifest increased levels and activity of this proteasome isoform. Here, we report our efforts to discover fragment-sized inhibitors of the human immunoproteasome. The screening of an in-house library of structurally diverse fragments resulted in the identification of benzo[d]oxazole-2(3H)-thiones, benzo[d]thiazole-2(3H)-thiones, benzo[d]imidazole-2(3H)-thiones, and 1-methylbenzo[d]imidazole-2(3H)-thiones (with a general term benzoXazole-2(3H)-thiones) as inhibitors of the chymotrypsin-like (β5i) subunit of the immunoproteasome. A subsequent structure-activity relationship study provided us with an insight regarding growing vectors. Binding to the β5i subunit was shown and selectivity against the β5 subunit of the constitutive proteasome was determined. Thorough characterization of these compounds suggested that they inhibit the immunoproteasome by forming a disulfide bond with the Cys48 available specifically in the β5i active site. To obtain fragments with biologically more tractable covalent interactions, we performed a warhead scan, which yielded benzoXazole-2-carbonitriles as promising starting points for the development of selective immunoproteasome inhibitors with non-peptidic scaffolds.

Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action

In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions.

Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators

Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.